# Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects

> **NCT05265676** · PHASE1 · COMPLETED · sponsor: **Venus Remedies Limited** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Enoxaparin Sodium (Venus Remedies Limited)
- **DRUG:** Enoxaparin Sodium (Sanofi)

## Key facts

- **NCT ID:** NCT05265676
- **Lead sponsor:** Venus Remedies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-26
- **Primary completion:** 2021-03-07
- **Final completion:** 2021-03-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265676, "Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05265676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*